Vaccines based on abnormal self-antigens as tumor-associated antigens: Immune regulation

Adam M. Farkas, Olivera J. Finn

Research output: Contribution to journalReview articlepeer-review

24 Scopus citations

Abstract

Abnormal expression of " self" antigens on tumors compared with normal cells provides opportunities and challenges for development of cancer vaccines. We review recent work in pre-clinical transgenic mouse models and in clinical trials that has elucidated multiple regulatory mechanisms that interfere with the induction of effective immunity. We discuss these as being either part of the normal function of the immune system or being driven by the tumor microenvironment. Collectively this work shows that it is possible to design vaccines based on tumor-associated antigens and elicit effective immunity against abnormal expression of these antigens on tumors without causing autoimmunity.

Original languageEnglish
Pages (from-to)125-131
Number of pages7
JournalSeminars in Immunology
Volume22
Issue number3
DOIs
StatePublished - Jun 2010
Externally publishedYes

Keywords

  • Cancer vaccine
  • Clinical trial
  • Self-tolerance
  • Transgenic mice
  • Tumor antigen

Fingerprint

Dive into the research topics of 'Vaccines based on abnormal self-antigens as tumor-associated antigens: Immune regulation'. Together they form a unique fingerprint.

Cite this